scholarly journals COLCHICINE IN PHARMACOTHERAPY OF CARDIOVASCULAR DISEASES IN PATIENTS WITH HYPERURICEMIA, WITH RHEUMATIC DISEASES AND COVID-19

2022 ◽  
pp. 2-2
Author(s):  
L.E. Sivordova ◽  
Yu.V. Polyakova ◽  
E.V. Papichev ◽  
Y.R. Akhverdyan ◽  
B.V. Zavodovskiy
Keyword(s):  
Cardiovascular Diseases ◽  
Rheumatic Diseases

Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative

2016 ◽  
Vol 75 (6) ◽  
pp. 965-973 ◽  
Author(s):  
Athan Baillet ◽  
Laure Gossec ◽  
Loreto Carmona ◽  
Maarten de Wit ◽  
Yvonne van Eijk-Hustings ◽  
...  
Keyword(s):  
Cardiovascular Diseases ◽  
Literature Review ◽  
Rheumatic Diseases ◽  
Daily Practice ◽  
Gastrointestinal Diseases ◽  
Inflammatory Rheumatic Diseases ◽  
Dissemination And Implementation ◽  
Consensus Process ◽  
European League Against Rheumatism ◽  
Chronic Inflammatory Rheumatic Diseases

In chronic inflammatory rheumatic diseases, comorbidities such as cardiovascular diseases and infections are suboptimally prevented, screened for and managed. The objective of this European League Against Rheumatism (EULAR) initiative was to propose points to consider to collect comorbidities in patients with chronic inflammatory rheumatic diseases. We also aimed to develop a pragmatic reporting form to foster the implementation of the points to consider. In accordance with the EULAR Standardised Operating Procedures, the process comprised (1) a systematic literature review of existing recommendations on reporting, screening for or preventing six selected comorbidities: ischaemic cardiovascular diseases, malignancies, infections, gastrointestinal diseases, osteoporosis and depression and (2) a consensus process involving 21 experts (ie, rheumatologists, patients, health professionals). Recommendations on how to treat the comorbidities were not included in the document as they vary across countries. The literature review retrieved 42 articles, most of which were recommendations for reporting or screening for comorbidities in the general population. The consensus process led to three overarching principles and 15 points to consider, related to the six comorbidities, with three sections: (1) reporting (ie, occurrence of the comorbidity and current treatments); (2) screening for disease (eg, mammography) or for risk factors (eg, smoking) and (3) prevention (eg, vaccination). A reporting form (93 questions) corresponding to a practical application of the points to consider was developed. Using an evidence-based approach followed by expert consensus, this EULAR initiative aims to improve the reporting and prevention of comorbidities in chronic inflammatory rheumatic diseases. Next steps include dissemination and implementation.

scholarly journals Role of Adipokines in Atherosclerosis: Interferences with Cardiovascular Complications in Rheumatic Diseases

2012 ◽  
Vol 2012 ◽  
pp. 1-14 ◽  
Author(s):  
Morena Scotece ◽  
Javier Conde ◽  
Rodolfo Gómez ◽  
Verónica López ◽  
Jesús Pino ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Cardiovascular Diseases ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Cardiovascular Complications ◽  
Risk Of Mortality ◽  
Increased Risk ◽  
Pathologic Alteration ◽  
Holistic Vision

Patients with rheumatic diseases have an increased risk of mortality by cardiovascular events. In fact, several rheumatic diseases such as rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, and ankylosing spondylitis are associated with a higher prevalence of cardiovascular diseases (CVDs). Although traditional cardiovascular risk factors have been involved in the pathogenesis of cardiovascular diseases in rheumatic patients, these alterations do not completely explain the enhanced cardiovascular risk in this population. Obesity and its pathologic alteration of fat mass and dysfunction, due to an altered pattern of secretion of proinflammatory adipokines, could be one of the links between cardiovascular and rheumatic diseases. Indeed, the incidence of CVDs is augmented in obese individuals with rheumatic disorders. Thus, in this paper we explore in detail the relationships among adipokines, rheumatic diseases, and cardiovascular complications by giving to the reader a holistic vision and several suggestions for future perspectives and potential clinical implications.

scholarly journals A Pilot Study: Hypertension, Endothelial Dysfunction and Retinal Microvasculature in Rheumatic Autoimmune Diseases

2021 ◽  
Vol 10 (18) ◽  
pp. 4067
Author(s):  
Ahmed Mahdy ◽  
Martin Stradner ◽  
Andreas Roessler ◽  
Bianca Brix ◽  
Angelika Lackner ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Cardiovascular Risk ◽  
Cardiovascular Diseases ◽  
Endothelial Dysfunction ◽  
Autoimmune Diseases ◽  
Rheumatic Diseases ◽  
Control Group ◽  
Autoimmune Rheumatic Diseases ◽  
Retinal Microvasculature ◽  
Significant Difference

Background: The etiology of autoimmune rheumatic diseases is unknown. Endothelial dysfunction and premature atherosclerosis are commonly seen in these patients. Atherosclerosis is considered one of the main causes of cardiovascular diseases. Hypertension is considered the most important traditional cardiovascular risk. This case-control study aimed to investigate the relationship between autoimmune diseases and cardiovascular risk. Methods: This study was carried out in patients with rheumatoid arthritis, RA (n = 10), primary Sjögren syndrome, PSS (n = 10), and healthy controls (n = 10). Mean blood pressure (MBP), systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse wave velocity (PWV, an indicator of arterial stiffness) were assessed via a Vicorder device. Asymmetric dimethylarginine (ADMA) was measured via ELISA. Retinal photos were taken via a CR-2 retinal camera, and retinal microvasculature analysis was carried out. T-tests were conducted to compare the disease and control groups. ANOVA and ANOVA—ANCOVA were also used for the correction of covariates. Results: A high prevalence of hypertension was seen in RA (80% of cases) and PSS (40% of cases) compared to controls (only 20% of cases). Significant changes were seen in MBP (RA 101 ± 11 mmHg; PSS 93 ± 10 mm Hg vs. controls 88 ± 7 mmHg, p = 0.010), SBP (148 ± 16 mmHg in RA vs. 135 ± 16 mmHg in PSS vs. 128 ± 11 mmHg in control group; p = 0.007), DBP (77 ± 8 mmHg in RA, 72 ± 8 mmHg in PSS vs. 67 ± 6 mmHg in control; p = 0.010 in RA compared to the controls). Patients with PSS showed no significant difference as compared to controls (MBP: p = 0.240, SBP: p = 0.340, DBP: p = 0.190). Increased plasma ADMA was seen in RA (0.45 ± 0.069 ng/mL) and PSS (0.43 ± 0.060 ng/mL) patients as compared to controls (0.38 ± 0.059 ng/mL). ADMA in RA vs. control was statistically significant (p = 0.022). However, no differences were seen in ADMA in PSS vs. controls. PWV and retinal microvasculature did not differ across the three groups. Conclusions: The prevalence of hypertension in our cohort was very high. Similarly, signs of endothelial dysfunction were seen in autoimmune rheumatic diseases. As hypertension and endothelial dysfunction are important contributing risk factors for cardiovascular diseases, the association of hypertension and endothelial dysfunction should be monitored closely in autoimmune diseases.

scholarly journals Autoimmune Rheumatic Diseases and Vascular Function: The Concept of Autoimmune Atherosclerosis

2021 ◽  
Vol 10 (19) ◽  
pp. 4427
Author(s):  
Ahmed M. Hedar ◽  
Martin H. Stradner ◽  
Andreas Roessler ◽  
Nandu Goswami
Keyword(s):  
Cardiovascular Diseases ◽  
Autoimmune Diseases ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Vascular Function ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Organ Damage ◽  
Unknown Etiology ◽  
Autoimmune Rheumatic Diseases

Autoimmune rheumatic diseases (AIRDs) with unknown etiology are increasing in incidence and prevalence. Up to 5% of the population is affected. AIRDs include rheumatoid arthritis, system lupus erythematosus, systemic sclerosis, and Sjögren’s syndrome. In patients with autoimmune diseases, the immune system attacks structures of its own body, leading to widespread tissue and organ damage, which, in turn, is associated with increased morbidity and mortality. One third of the mortality associated with autoimmune diseases is due to cardiovascular diseases. Atherosclerosis is considered the main underlying cause of cardiovascular diseases. Currently, because of finding macrophages and lymphocytes at the atheroma, atherosclerosis is considered a chronic immune-inflammatory disease. In active inflammation, the liberation of inflammatory mediators such as tumor necrotic factor alpha (TNFa), interleukine-6 (IL-6), IL-1 and other factors like T and B cells, play a major role in the atheroma formation. In addition, antioxidized, low-density lipoprotein (LDL) antibodies, antinuclear antibodies (ANA), and rheumatoid factor (RF) are higher in the atherosclerotic patients. Traditional risk factors like gender, age, hypercholesterolemia, smoking, diabetes mellitus, and hypertension, however, do not alone explain the risk of atherosclerosis present in autoimmune diseases. This review examines the role of chronic inflammation in the etiology—and progression—of atherosclerosis in autoimmune rheumatic diseases. In addition, discussed here in detail are the possible effects of autoimmune rheumatic diseases that can affect vascular function. We present here the current findings from studies that assessed vascular function changes using state-of-the-art techniques and innovative endothelial function biomarkers.

scholarly journals RISK FACTORS FOR CORONARY ARTERIES DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS

2020 ◽  
Vol 20 (1) ◽  
pp. 95-99
Author(s):  
V.M. Zhdan ◽  
V.G. Lebid ◽  
H.S. Khaimenova ◽  
Yu.A. Isheikina
Keyword(s):  
Rheumatoid Arthritis ◽  
Cardiovascular Diseases ◽  
General Population ◽  
Coronary Arteries ◽  
Rheumatic Diseases ◽  
Health Care Professionals ◽  
Early Stage ◽  
Main Group ◽  
Control Group ◽  
X Rays

Now health care professionals who manage patients and stick to holistic patient-cantered approach are facing the problem of “polymorbidity”. The most common conditions complicating rheumatic diseases are cardiovascular diseases, interstitial lung disease, osteoporosis, chronic kidney disease, malignancies and depression. Despite the success in treatment of rheumatoid arthritis, the mortality rate in this category of patients remains higher than in the general population. This is associated with the acceleration of atherosclerosis progression and the early-age onset of coronary arteries disease. Therefore, rheumatoid arthritis is considered as a predictor of coronary arteries disease. The incidence of myocardial infarction, heart failure, and sudden coronary death in patients with rheumatoid arthritis is found to be 3 to 5 times higher than in the general population. The purpose of the present study was to estimate and evaluate comorbidity status in patients with rheumatoid arthritis. The study was performed at the at the Regional Medical and Diagnostic Centre of Rheumatologic Diseases, M.V. Sklifosovskyi Poltava Regional Clinical Hospital, which is the clinical base of the Department of Family Medicine and Therapy, Ukrainian Medical Stomatological Academy. The study included 135 patients with rheumatoid arthritis aged 32 – 65, who made up the main group. The control group consisted of 30 patients without autoimmune diseases, inflammatory conditions and other diseases in acute phase. All patients stated the consent to participate in the study in writing. During the study, all the participants passed through clinical examination including blood tests, urine tests, blood biochemistry, electrocardiography, echocardiography, X-rays of the joints, and ultrasound examinations (by using an apparatus of class “Radmir ultima”). 68.2% of the patients in the main group suffering from rheumatoid arthritis were found out to have different comorbidities compared with the control group. Cardiovascular diseases and especially coronary arteries disease were detected in 42.3% of cases and found out as the most prevalent comorbid diseases in the patients with rheumatoid arthritis. We also revealed the high prevalence of dyslipidemia (73, 4% of cases). It is necessary to underline that 75% of patients in the main group were diagnosed to have even 2 or more comorbidities. According to the results obtained, the majority of the patients suffering from rheumatoid arthritis have comorbidities, which can seriously affect the course of rheumatic diseases and influence the treatment. Management of patients with rheumatoid arthritis and comorbid conditions should be supported by rheumatologists, family doctors, internists in order to evaluate all polymorbidities in their interactions and to provide proper assistance for patients in making their therapeutic course decisions. Of course, this requires novel data from experts to improve diagnostic and treatment approaches of rheumatoid arthritis in its early stage.

Inflammageing in the cardiovascular system: mechanisms, emerging targets, and novel therapeutic strategies

2020 ◽  
Vol 134 (17) ◽  
pp. 2243-2262
Author(s):  
Danlin Liu ◽  
Gavin Richardson ◽  
Fehmi M. Benli ◽  
Catherine Park ◽  
João V. de Souza ◽  
...  
Keyword(s):  
Cardiovascular Diseases ◽  
Cardiovascular System ◽  
Nlrp3 Inflammasome ◽  
Molecular Mechanisms ◽  
Molecular Targets ◽  
Therapeutic Interventions ◽  
Low Grade ◽  
Cardiovascular Research ◽  
Inflammatory Processes ◽  
Ach Receptors

Abstract In the elderly population, pathological inflammation has been associated with ageing-associated diseases. The term ‘inflammageing’, which was used for the first time by Franceschi and co-workers in 2000, is associated with the chronic, low-grade, subclinical inflammatory processes coupled to biological ageing. The source of these inflammatory processes is debated. The senescence-associated secretory phenotype (SASP) has been proposed as the main origin of inflammageing. The SASP is characterised by the release of inflammatory cytokines, elevated activation of the NLRP3 inflammasome, altered regulation of acetylcholine (ACh) nicotinic receptors, and abnormal NAD+ metabolism. Therefore, SASP may be ‘druggable’ by small molecule therapeutics targeting those emerging molecular targets. It has been shown that inflammageing is a hallmark of various cardiovascular diseases, including atherosclerosis, hypertension, and adverse cardiac remodelling. Therefore, the pathomechanism involving SASP activation via the NLRP3 inflammasome; modulation of NLRP3 via α7 nicotinic ACh receptors; and modulation by senolytics targeting other proteins have gained a lot of interest within cardiovascular research and drug development communities. In this review, which offers a unique view from both clinical and preclinical target-based drug discovery perspectives, we have focused on cardiovascular inflammageing and its molecular mechanisms. We have outlined the mechanistic links between inflammageing, SASP, interleukin (IL)-1β, NLRP3 inflammasome, nicotinic ACh receptors, and molecular targets of senolytic drugs in the context of cardiovascular diseases. We have addressed the ‘druggability’ of NLRP3 and nicotinic α7 receptors by small molecules, as these proteins represent novel and exciting targets for therapeutic interventions targeting inflammageing in the cardiovascular system and beyond.

Self-efficacy and quality of life among people with cardiovascular diseases: A meta-analysis.

2018 ◽  
Vol 63 (2) ◽  
pp. 295-312 ◽  
Author(s):  
Anna Banik ◽  
Ralf Schwarzer ◽  
Nina Knoll ◽  
Katarzyna Czekierda ◽  
Aleksandra Luszczynska
Keyword(s):  
Quality Of Life ◽  
Cardiovascular Diseases ◽  
Self Efficacy ◽  
Meta Analysis
Sign in / Sign up

Export Citation Format

Share Document